Navigation Links
Estradiol Guards Against Osteoporosis

Researchers find a novel pathway by which estradiol, the primary estrogen in humans maintains bone density. This function is significant as it aids in avoiding osteoporosis. //

It is well known that estrogen is essential for healthy bone, and that when the production of estrogen is reduced, as occurs normally in postmenopausal women and pathogenically after exposure to radiation or chemotherapeutic drugs, bones become brittle and break easily. However, the mechanisms involved aren’t clearly understood.

The new study found that one way estradiol helps to maintain bone density is by stopping the activation of an enzyme known as caspase-3. Also called the executioner caspase, caspase-3 is the central player in initiating the process of apoptosis, or programmed cell death of osteoblasts, the bone cells that aid in the growth and development of new bone and teeth.

Results of the study will be presented tomorrow (Friday, March 23) at the International Association of Dental Research meeting in New Orleans. Peter G. Bradford, Ph.D., senior author on the study said of the results: "Basic and clinical studies have shown that estrogens can prevent both bone loss and reduce the incidence of bone fractures. Our research at the molecular and cellular level suggests that the underlying basis of this protective effect of estrogens involves the prevention of apoptosis in osteoblasts and that the key event in this prevention is the inhibition of caspase-3 activity."

Bradford is an associate professor of pharmacology and toxicology in the UB School of Medicine and Biomedical Sciences and associate professor of oral biology in the UB School of Dental Medicine. Kenneth V. Gerace, a third-year dental student in his laboratory, is first author on the study.

To determine the effect of estradiol on caspase-3 activity, one group of human osteoblasts was treated with estradiol for 24 hours and another group was not. Both groups then w ere exposed for 24 hours to a drug called etoposide, a cancer chemotherapeutic drug that promotes apoptosis.

Results showed that caspace-3 activity decreased in cells treated with estrogen, but increased in cells not treated with estrogen. "These findings support our hypotheses that the anti-osteoporotic effects of estradiol may result in part from its anti-apoptotic effects on osteoblasts," said Bradford.

"We now are investigating the biochemical mechanisms that mediate the estrogen-dependent inhibition of caspase-3 activity in osteoblasts and whether other pharmacological or nutritional agents might mimic or aid this action of estradiol."

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Delhi Police, Home Guards to Guard LNGP
2. AAI Pharma Files Lawsuit Against Dr. Reddys Laboratories
3. Diabetics Need to Guard Against Nail Fungus
4. New Weapon Against Germs
5. Estrogen Found To Protect the Colon Against Cancer
6. Diet Found To Offer Protection Against Leukemia
7. Olive Oil Found To Offer A Protective Effect Against Breast Cancer
8. WHO Issues Caution Against Bird Flu Epidemic
9. New Supplement Found To Be Effective Against Sunburn
10. Intense Fight Against Polio In India Gets Results
11. Prime Minister Manmohan Against Incentive-Based Population Control
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
Breaking Medicine Technology: